Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Janus kinase inhibitors help some people with severe alopecia areata regrow hair, but not everyone responds, and relapses can happen.

Janus kinase inhibitors reduce inflammation markers in severe alopecia areata patients.

Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.

TNF-α blockers and IL inhibitors improve symptoms in most patients with severe scalp condition, but more research is needed.

Baricitinib works better for alopecia areata in patients not previously treated with tofacitinib.

Female-pattern hair loss may involve an autoimmune-like process, suggesting new treatment options.

The study concluded that immune cells attacking hair follicles cause hair loss in alopecia, with genetics and environment also playing a role, and highlighted the potential of certain treatments.

Baricitinib helps regrow hair in severe alopecia areata but has side effects like infections and headaches.

JAK inhibitors can help treat alopecia areata but have risks and high costs.

Quercetin can boost hair follicle stem cell growth in cashmere goats, potentially improving cashmere quality.

Chinese patients with alopecia areata value JAK inhibitors but worry about side effects and relapse, highlighting the need for education and support.

Baricitinib is more effective than tofacitinib for hair regrowth in alopecia patients.

Netherton syndrome has two subtypes with shared immune traits but different allergic and immune responses, suggesting targeted treatments.

Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.

Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.

Tyrosine kinases are important in skin autoimmune diseases and could be targets for new treatments.

Certain immune cells contribute to skin autoimmune diseases, and some treatments can reverse hair loss in these conditions.

Tofacitinib helped regrow hair in patients with alopecia, with few side effects.

Cepharanthine may help treat COVID-19 by targeting similar pathways as other inflammatory diseases.

New targeted immunotherapies are improving treatment for inflammatory skin diseases.

Activating Tgr5 may help treat hair loss and bone loss.

The role of antibodies in alopecia is unclear, but JAK inhibitors show promise for treatment.

Oral JAK inhibitors effectively treat alopecia areata and are generally well-tolerated.

Deucravacitinib may help treat various immune diseases beyond psoriasis, but more research is needed.

Biological factors are crucial for developing new hair restoration treatments.

The link between anabolic agents and colorectal cancer risk is unclear.

Tofacitinib successfully treated hair loss in a Crohn's disease patient who previously used adalimumab.

Upadacitinib can effectively regrow hair in alopecia areata patients without worsening sarcoidosis.

IFN-γ production by CD4 T cells is crucial for causing alopecia areata.

Hair follicles are key to treating vitiligo and alopecia areata, but challenges exist.